Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials

被引：0

作者：

Giannatempo, Patrizia

Machiels, Jean-Pascal H.

Sassa, Naoto

Arija, Jose Angel Arranz

Fujii, Yasuhisa

Su, Wen-Pin

Keam, Bhumsuk

Culine, Stephane

Shen, Ying-Chun

Munoz-Langa, Jose

Sarid, David Leonid

Aarts, Maureen J. B.

Calabro, Fabio

Rosenbaum, Eli

Goldman, Olesya

Moreno, Blanca Homet

Bavle, Abhishek Amar

Xu, Jin Zhi

Rha, Sun Young

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[2] UCLouvain, Clin Univ St Luc, Brussels, Belgium

[3] Aichi Med Univ, Nagakute, Japan

[4] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[5] Tokyo Med & Dent Univ Hosp, Tokyo, Japan

[6] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[7] Seoul Natl Univ Hosp, Seoul, South Korea

[8] St Louis Hosp, Paris, France

[9] Natl Taiwan Univ Hosp, Taipei, Taiwan

[10] Hosp Univ & Politecn La Fe, Valencia, Spain

[11] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[12] Maastricht Univ, Med Ctr, Maastricht, Netherlands

[13] UPMC Salvator Mundi Int Hosp, Rome, Italy

[14] Rabin Med Ctr, Inst Oncol, Clin Trials Dept, Petah Tiqwa, Israel

[15] Meir Med Ctr, Oncol Inst, Kefar Sava, Israel

[16] Merck & Co Inc, Rahway, NJ USA

[17] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4512

引用

页数：1